1.145EUR+2.23%Mkt Cap: —P/E: —1d ago
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-…
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$375.50BUSDP/E 122.7
$341.92BUSDP/E 24.5
$348.81BUSDP/E 25.0
$279.13BUSDP/E 22.3
$274.07BUSDP/E 23.6
$240.45BUSDP/E 24.5
$231.49BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$139.84BUSDP/E 32.2
$138.11BUSDP/E 14.9
Key Statistics
Company
Market Cap—
Enterprise Value33.96M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.36M $
Revenue/Share—
Last Price1.145 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryGB
SectorHealthcare
Industry—
ISINNL00150002Q7
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-4.66
EV/Revenue—
P/S—
P/B21.42
EPS (TTM)-0.63
EPS (Forward)—
52W Range
1.120100% of range1.145
52W High1.145 EUR
52W Low1.120 EUR
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-285.21%
ROA-80.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.72M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-2.58M $
Net Debt/EBITDA0.35
Balance Sheet
Debt/Equity4.86
Current Ratio4.56
Quick Ratio4.03
Book Value/Sh0.0530 EUR
Cash/Share0.0830 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.8.21M
Float26.35M
Insiders17.99%
Institutions8.91%
Technical
SMA 507.298 (-84.3%)
SMA 2009.935 (-88.5%)
Beta1.45
S&P 52W Chg20.80%
Avg Vol (30d)35
Avg Vol (10d)10.28K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—